TG Therapeutics shares rise on buyout rumors with potential 45-50% acquisition premium.

Shares of TG Therapeutics increased following rumors that a larger biopharma company with a market cap between $20-40 billion is considering acquiring TG. The company's growth, especially from its drug Briumvi and recent advances in formulation, make it an attractive takeover target. Analysts see a potential acquisition premium of 45-50%, valuing TG Therapeutics at $73-76 per share. Even without a buyout, the company is well-positioned for long-term growth due to Briumvi's expansion and pipeline diversification. Possible acquirers include Biogen, Incyte, and Sanofi, with Sanofi seen as a strong strategic fit despite its larger market cap.